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Hypertension is both an important cause and consequence of chronic kidney disease. Evidence from numerous clinical trials has
demonstrated the beneﬁt ofblood pressure control. However,it remains unclear whether availableresults could be extrapolated to
patientswithchronickidneydiseasesbecausemoststudiesonhypertensionhaveexcluded patientswithkidneyfailure.Inaddition,
chronickidneydiseaseencompassesalargegroupofclinicaldisorderswithheterogeneous naturalhistoryandpathogenesis.In this
paper, we review current evidence supporting treatment of hypertension in various forms of chronic kidney disease and highlight
some of the gaps in the extant literature.
1.Introduction
Hypertension is a major risk factor for cardiovascular and
renal disease. Conversely, chronic kidney disease (CKD) is
the most common form of secondary hypertension and
mounting evidence suggests it is an independent risk factor
for cardiovascular morbidity and mortality [1–3]. The
prevalence of CKD has been better characterized since the
National Kidney Foundation issued a standard classiﬁcation
based on the levelof glomerular ﬁltration rate (GFR)and the
presence or absence of evidence of renal injury. Patients with
stages 1 and 2 CKD need to show evidence of renal injury
(e.g., proteinuria), and GFR of ≥90 and 60–89mL/minute,
respectively. Stages 3, 4, and 5 correspond to GFR of 30–59,
15–29, and <15 mL/minute, respectively, regardless of any
other evidence of renal damage [4]. It is estimated that 10–
13% of adults in the USA suﬀer from some degree of CKD
[5].
Evidence from a large number ofclinical trials has clearly
demonstrated that eﬀective treatment ameliorates the harm-
ful eﬀects of uncontrolled hypertension [6]. Unfortunately,
most trials have excludedpatients with CKD, and those trials
that speciﬁcally targeted CKD patients primarily focused on
progression of renal disease as the primary clinical endpoint.
In this paper, we review the epidemiology, pathophysiology,
and therapy of hypertension in CKD and highlight the gaps
in the available evidence.
2.Epidemiology
Approximately one in three adults in the United States
has hypertension [7]. The prevalence of hypertension is
higher among patients with CKD, progressively increasing
with the severity of CKD. Based on a national survey of
representative sample of noninstitutionalized adults in the
USA, it is estimated that hypertension occurs in 23.3% of
individuals without CKD, and 35.8% of stage 1, 48.1% of
stage 2, 59.9% of stage 3, and 84.1% of stage 4-5 CKD
patients [8]. Prevalence of hypertension also varies with the
cause of CKD; strong association with hypertension was
reportedinpatientswithrenalarterystenosis(93%),diabetic
nephropathy (87%), and polycystic kidney disease (74%)
[9].
Despite the high prevalence of hypertension and avail-
ability of eﬀective medications, only a minority of patients
achieve recommended treatment goals. However, this situa-
tionmaybechangingin thegeneralpopulation.Comparison
o fr e c e n tc o h o r t sw i t hp a t i e n t si ne a r l i e rd e c a d e ss h o w st h a t
awareness and control of hypertension have improved from2 International Journal of Hypertension
69% to 80% and 27% to 50%, respectively [7]. Reports on
CKD patients enrolled in prospective observational studies
have described rates of awareness and control of hyperten-
sion as similar to current levels in the general population
[10, 11]. Population data, however, indicate that not only
awareness and control of hypertension but also the odds of
adequate treatment of other cardiovascular risk factors are
lower in those with CKD [12, 13]. Possible explanations to
this discrepancy are the unintended consequence of study
participation on clinical care or adherence, and diﬀerences
in composition of diﬀerent study populations. Although
a sizeable proportion of CKD patients requires multiple
antihypertensive agents—32% were taking four or more
anti-hypertensive drugs in one study [10]—nonadherence
does not appear to be more common than in patients
without CKD [11]. The picture is complicated further by
t h eh i g hp r e v a l e n c eo fm a s k e da n dw h i t e - c o a th y p e r t e n s i o n
among CKD patients, which results in misclassiﬁcation of
true blood pressure; 24-hour ambulatory blood pressure
monitoring may, therefore, be necessary to reliably diagnose
hypertension and assess attainment of blood pressure goals
[14].
Hypertension is also extremely common among patients
on hemodialysis or peritoneal dialysis, and those who have
undergone renal transplant. Unlike in patients on peritoneal
dialysis, removal ﬂuid in patients on intermittent-thrice
weekly hemodialysis is episodic, leading to large diﬀerences
between pre-, post-, and interdialysis blood pressure. This
variation in blood pressure impedes a clear deﬁnition of
hypertension and target blood pressure in hemodialysis
patients. Agarwal and Lewis proposed a cutoﬀ predialysis
blood pressure of 150/85 to deﬁne hypertension and control;
they showed predialysis blood pressure >150/85 to have 80%
sensitivity in predicting elevated interdialytic ambulatory
blood pressure [15]. Based on this deﬁnition, they found
86% of hemodialysis patients had hypertension, of which
only 30% had adequate control [16]. Similar prevalence of
hypertension was reported in peritoneal dialysis patients and
over 70% of renal transplant recipients have hypertension
[17, 18].
Intense controversy surrounds the beneﬁt of blood
pressure control in dialysis patients [19]. Analyses of registry
data show a U-shaped relationship between blood pressure
and mortality. By contrast, studies of selected patients at
low risk for cardiovascular disease replicate the observation
in the general population that the risk of adverse car-
diovascular outcome increases with blood pressure. While
the exact pathophysiologic basis for this discrepancy is
unclear, it has been suggested that high mortality in dialysis
patients with lower blood pressure is due to coexisting
severe cardiac disease. In support of this explanation is
the favorable outcome seen in the intervention arm of the
Frequent Hemodialysis Network (FHN) Daily Trial despite
having lower pressure than the control group [20]. In renal
transplant recipients,observationalstudiessuggest that post-
transplant hypertension is an independent risk factor for
graft failure and death, and that adequate blood pressure
control reduces this risk [21, 22].
3.Pathophysiologic Considerations
Thekidneysplaysuchavitalroleinlong-termbloodpressure
regulation that Guyton argued that sustained hypertension
could not occur in the absence of impairment of renal
handling of sodium [23]. In fact, virtually all forms of exper-
imental and human hypertension exhibit impaired sodium
excretion by the kidneys at normal blood pressure [24]. In
his seminal experiments using large animals and isolated
perfused kidneys, Guyton showed that acute rise in blood
pressure results in brisk increase in renal sodium excretion
and normalization of blood pressure. Conversely, sodium
loading increased blood pressure only when renal sodium
excretion was constrained by ablation of 70% of renal mass
oradministration of angiotensin oraldosterone.Underthese
circumstances, rise in blood pressure was initially mediated
by expansion of extracellular ﬂuid (ECF) volume, despite
reduction in total peripheral resistance. At this stage, the rise
in blood pressure is mediated by increased cardiac output;
this manifests as predominantly systolic hypertension. Over
time, however, ECF volume and cardiac output normalize
and high blood pressure results from elevated peripheral
resistance, which increases diastolic blood pressure.
That subtle renal defects may underlie the pathogenesis
of essential hypertension in humans is supported further by
several lines of evidence. In a series of patients with renal
failure due to histologically proven hypertensive nephroscle-
rosis, transplant with kidneys from normotensive donors
resulted in the resolution of their hypertension [25]. It
has also been shown that normotensive individuals with
family history of hypertension respond to salt loading with
less natriuresis and higher blood pressure than those with
no family history [26]. Finally, hypertensive victims of
fatal accidents were endowed with fewer nephrons than
normotensive controls in an autopsy series [27]. The exact
natureofrenaldefectordefectsresponsibleforinappropriate
sodium excretion, or of factors that mediate the subsequent
rise in peripheral resistance, remains unclear.
The critical role of volume expansion in hypertension
due to CKD is underscored by the eﬀect of ultraﬁltration
or diuretics on blood pressure control in CKD patients.
Dialysis units that employ eight-hour thrice-weekly or short
daily hemodialysis report that only a minority of patients
require antihypertensive medications for blood pressure
control[28].This observationisconﬁrmed in theFHNDaily
Trial, which also showed improvement in the composite
outcome of death or left ventricular hypertrophy in the
more frequent dialysis group [20]. Similarly, better volume
and blood pressure control could be achieved by peritoneal
dialysis [29], or use of loop diuretics in earlier stages of CKD
[30].
Positive salt balance is the dominant but not the sole
factor in the genesis of hypertension in CKD. As noted
above, experimental evidence has clearly demonstrated that
hypertension dueto retention ofsalt and water is maintained
by increased peripheral resistance. This has been replicated
in hypertensive uremic humans [31]. Table 1 shows a list of
factors proposed to cause hypertension in CKD along with
their corresponding mechanisms.International Journal of Hypertension 3
Table 1: Selected factors that may cause hypertension in chronic
kidney disease∗.
Factor Dominant Mechanism
Impaired sodium excretion Expansion of ECF volume
Activation of RAS Direct vasoconstriction
Sympathetic activation
Sympathetic activation Direct vasoconstriction
Stimulation of renin release
Imbalance in prostaglandins or
kinins Vasoconstriction
Endothelin Direct vasoconstriction
Renal injury
Reduced nitric oxide Loss of vasodilator eﬀect
∗See text for detail. ECF: extracellular ﬂuid; RAS: renin-angiotensin system.
Activation of the renin-angiotensin system (RAS) has
been well documented in dialysis patients with uncon-
trolled hypertension despite optimized ultraﬁltration [32].
Treatment of such patients with bilateral nephrectomy or
inhibitors of RAS has been shown to result in control of
blood pressure, suggesting failing kidneys as the source of
excess renin [32, 33]. In addition to its direct pressor eﬀect,
it is possible that the activation of the RAS may contribute
to hypertension in CKD by stimulating the sympathetic
nervous system. In microneurographic studies, patients
with CKD have increased sympathetic nerve activity that
responds to angiotensin-converting enzyme (ACE) inhibi-
tionorbilateralnephrectomy [34].Evenwhenrenal function
is well preserved, activation of the RAS is an important
factor in the pathogenesis of hypertension in polycystic
kidney disease, and is believed to be due to compression
of the renal vasculature by enlarging cysts [35]. Other
factors proposed to explain increased vascular resistance in
CKD include increased production of endothelin [36]a n d
endogenousdigitalis-like substance [37]; reduced generation
of vasodilators such as nitric oxide [38] and kinins [39];
and imbalance between vasodilator and vasoconstrictor
prostaglandins [40]. While the primacy of oxidative stress
in hypertension and chronic kidney disease is unknown, it
commonly accompanies both disorders and is believed to
contribute in part to their pathogenesis [41].
G r a f tf u n c t i o ni sa ni m p o r t a n tp r e d i c t o ro fh y p e r t e n -
sion after renal transplant [18]. In addition, calcineurin
inhibitors(tacrolimusand cyclosporine)and glucocorticoids
contribute to the pathogenesis of hypertension in kidney
transplant recipients. Calcineurin inhibitors possess vas-
oconstrictor properties, but the exact mechanism is not
known. Disturbances in the biology of vasoactive substances
discussed above and the eﬀect on smooth muscle calcium
metabolism have been described [18, 42]. Stenosis of the
renal artery of a transplant, or of arteries proximal to
the arterial anastomosis, is an infrequent but potentially
reversible cause of hypertension after renal transplant.
4.TreatmentofHypertensionin
Chronic KidneyDisease
Patients with CKD are more likely to die, largely from card-
iovascular disease, than require dialysis [43, 44]. Once they
develop end-stage renal disease (ESRD), dialysis patients
have eight times the mortality rate of their age-matched
counterparts in the general population, with cardiovascular
causes accounting for more than 50% of deaths [45]. It
is, therefore, critically important to control modiﬁable risk
factors (e.g., hypertension) in this high-risk group.
5.BloodPressureGoals
The latest national guidelines from the Joint National
Commission on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure VII (JNC VII) and
the Kidney Disease Quality Outcome Initiative (K/DOQI)
recommend blood pressure <130/80 as the goal of treatment
f o rp a t i e n t sw i t hC K D[ 46, 47]. As discussed below, there
is consistent evidence that attainment of this blood pressure
goalretards progressionofrenal disease inpatientswithCKD
and proteinuria. It is, however, questionable whether this
blood pressure goal is applicable to all patients with CKD.
First, in patients without signiﬁcant proteinuria, there are
no data supporting more aggressive blood pressure control
than what is recommendedfor hypertensive patientswithout
CKD (<140/90). Second, the safety of intensive blood
pressure lowering in patients older than 70 years, who have
been largely excluded from most clinical trials examining
the beneﬁt of blood pressure control, is not established.
Third, secondary analyses ofprospective studies indicatethat
patients with CKD may incur excess risk of stroke when
systolic blood pressure is lowered below 120mmHg, or of
myocardial infarction when diastolic blood pressure is low-
ered below 80mmHg. [48, 49]. The beneﬁt of treating iso-
latedsystolichypertensioninpatientswithCKDhasnotbeen
directly tested in a clinical trial. The Systolic Hypertension in
the Elderly Program, which excludedpatientswith renal dys-
function, has shown that treatment of systolic hypertension
reduces morbidity and mortality; it is however, important to
note that the mean systolic blood pressure attained in the
active treatment arm was 143mmHg [50]. Since patients
with CKD tend to be older and have more cardiovascular
risk factors, it is advisable to individualize treatment in
some patients, especially those who do not have signiﬁcant
proteinuria.
Most clinical trials that examined control of blood pres-
sure in patients with CKD used progression of renal disease
as their primary endpoint, and stratiﬁed their study pop-
ulation by the degree of proteinuria or etiology of kidney
disease. In the following sections, the evidence for beneﬁts
of blood pressure treatment will be discussed separately for
diabetic nephropathy, other proteinuric renal diseases, and
nonproteinuric nephropathy. Table 2 summarizes treatment
of hypertension in CKD according to the nature of kidney
disease.4 International Journal of Hypertension
Table 2: Summary of treatment of hypertension in chronic kidney
disease∗.
Disorder BP Goal Preferred Class
Diabetic nephropathy <130/80 ACEI/ARB
Nondiabetic proteinuric
nephropathy <130/80 ACEI/ARB
Nonproteinuric
nephropathy <140/90 Any
Renal transplant Unknown
Any; caution
with verapamil
or diltiazem
∗See text for details. BP: blood pressure; ACEI: angiotensin-converting
enzyme inhibitor; ARB: angiotensin-receptor blocker.
6.Treatmentof Hypertensionin
DiabeticNephropathy
It is generally accepted that treatment of diabetic nephropa-
thy should include an ACE inhibitor or angiotensin-receptor
blocker (ARB) to attain a blood pressure goal of less
than 130/80 mmHg. Most [51–55], but not all [56–58],
clinical trials that examined the impact of speciﬁc class of
antihypertensive agents on worsening of proteinuria or renal
function in diabetic nephropathy found that ACE inhibitors
or ARBs are renoprotective. In patients with type 1 diabetes,
treatment with captopril retarded progression of microalbu-
minuria (daily urinary excretion of albumin of 30–300mg)
to overt proteinuria [51, 52], and of overt nephropathy to
ESRD [53]. Two large clinical trials also showed that use
of the ARBs irbesartan and losartan in patients with overt
diabetic nephropathy due to type 2 diabetes reduced the risk
of progression of renal disease [54, 55].
The beneﬁt of attaining the currently recommended goal
blood pressure of <130/80 has not been directly tested in
clinical trials of diabetic nephropathy. Secondary analyses of
existing trials, however, suggest that lowering blood pressure
tothis levelmay improve renal and cardiovascular outcomes.
The United Kingdom Prospective Diabetes Study (UKPDS)
compared the eﬀectoflowering blood pressure below150/85
and 180/85 mmHg in patients with type 2 diabetes and
hypertension [59]. Patients with laser-requiring diabetic
retinopathy and serum creatinine >2mg/dL were excluded;
mean blood pressure attained in the tight- and usual-control
groups was 144/82 and 152/87mmHg, respectively, and
more than 80% of patients had urinary albumin excretion
<50mg/L. In a posthoc analysis of the original data, the
authors found no blood pressure threshold for the beneﬁcial
eﬀect of blood pressure lowering and recommended aiming
forsystolic bloodpressure of 120mmHgor lowerin diabetic
patients with hypertension [60].
The Irbesartan in Diabetic Nephropathy Trial (IDNT)
assessed the renoprotective eﬀects of adding irbesartan,
amlodipine, or placebo to standard antihypertensive regi-
mens [54]. All three groups had a median daily urinary
protein excretion of 1.9 grams, and the attained blood
pressure in the irbesartan, amlodipine, and placebo groups
was 140/77, 141/77, and 144/80mmHg, respectively. Sec-
ondary analyses of IDNT showed that progressive lowering
of blood pressure up to systolic blood pressure of 120mmHg
protects against cardiovascular events and deterioration of
renal function, but further reduction in blood pressure is
deleterious; a similar trend up to diastolic blood pressure
of 85mmHg was observed for cardiovascular but not renal
endpoints [49, 61].
The normotensive Appropriate Blood Pressure Control
in Diabetes (ABCD) and Modiﬁcation of Diet in Renal
Disease (MDRD) studies are two other trials that failed to
prove the value of lower blood pressure for their primary
endpoints, but suggested a beneﬁcial eﬀect in post-hoc
analyses [57, 58]. The normotensive ABCD trial compared
intensive with moderate blood pressure lowering using
nisoldipine or enalapril in normotensive patients with type
2 diabetes. Attained blood pressure in the intensive and
moderate treatment arms was 128/75 and 137/81mmHg,
respectively; corresponding rates of microalbuminuria were
21% and 25%. There was no diﬀerence in the rate of decline
of renal function—the primary endpoint—but lesser degree
of proteinuria was noted with intensive therapy. No diﬀer-
ence was noted between the nisoldipine and enalapril arms.
The MDRD study largely consisted of nondiabetic patients;
it compared the eﬀect of intensive versus usual blood
pressure control, and low versus high protein intake on renal
function. The study showed no diﬀerence in the primary
outcome between the diﬀerent arms, but subgroup analysis
showed that lowering mean blood pressure to 92 mmHg
(equivalent to 125/75mmHg) preserved renal function in
those with proteinuria of >3g/day ,or>1g/dayinasubset
with glomerular ﬁltration rate of 25–55 ml/min/1.73m2
[58, 62].
As the above summary shows, careful review of the
data that underpin the recommendation for lowering BP
to <130/80 in patients with diabetic nephropathy calls for
caution in applying the guideline universally; most studies
did not attain this level of control, and the recommendation
is based mainly on post hoc analysis. This is especially
true in light of the results of the Action to Control
Cardiovascular Risk in Diabetes Blood Pressure (ACCORD
BP) trial [63]. This large trial of diabetic patients with
cardiovascular disease or at least two additional risk factors
for cardiovascular disease evaluated the impact of lowering
systolic blood pressure below 120 or 140mmHg. Study
participants had mean serum creatinine of 0.9mg/dL and
minimal or no proteinuria. Despite attaining systolic blood
pressure of 119 and 135mmHg with intensive and standard
therapy, there was no diﬀerence in the composite primary
endpoint (nonfatal stroke, nonfatal myocardial infarction, or
cardiovascular death) or all-cause mortality between the two
groups. The intensive control group had lower risk of stroke,
but at the expense of higher rates of serious side eﬀects.
7.TreatmentinNondiabetic
ProteinuricNephropathy
Evidence from controlled clinical trials indicates that blood
pressure control limits the progression of nondiabeticInternational Journal of Hypertension 5
proteinuric renal disease. The MDRD study, as discussed
above, suggested that the degree of proteinuria determines
the beneﬁcial eﬀect derived from tight blood pressure
control [58]. Although no additional beneﬁt from use of
ACE inhibitors was found in the MDRD trial, subsequent
randomized controlled studies support the use of ACE
inhibitors for renoprotection, especially in those patients
with signiﬁcant proteinuria (daily urinary protein excretion
of 1gm or more) [64, 65]. Since these studies have not
attained blood pressure <130/80, the best available evidence
for targeting blood pressure below this level is obtained
from subgroup analysis of the MDRD study. Data on the
use of ARBs in nondiabetic proteinuric renal disease are
limited, but ARBs are generally believed to be equivalent to
ACEinhibitors[66].Unliketheirsupportforrenoprotection,
these studies do not provide adequate data on the impact of
blood pressure control on cardiovascular outcomes.
8.Treatmentin NonproteinuricNephropathy
The beneﬁt of tighter blood pressure control than <140/90,
or of the use of ACE inhibitors or ARBs, in nonproteinuric
nephropathy has not been established. In the African Amer-
ican Study of Kidney Disease and Hypertension (AASK),
patients were randomized to treatment with ramipril,
amlodipine, or metoprolol and to low and usual blood
pressure targets [67]. The amlodipine arm was terminated
prematurely because interim analysis implied that it had
worse outcome than those treated with ramipril. Approx-
imate two-thirds of the participants had urine protein-to-
creatinine ratio less than 0.22 (equivalent to 300mg/day)
at baseline. Attained blood pressure in the low- and
usual-blood-pressure groupswas128/78and 141/85mmHg,
respectively. There was no diﬀerence in the rate of progres-
sion of renal disease, but ramipril appeared more eﬀective
than amlodipine or metoprolol in decreasing the composite
secondary outcome of worsening renal function, ESRD, or
death. A long-term followup of the AASK cohort suggested
this beneﬁt accrued in those with higher levels of proteinuria
[68]. Absence of additional beneﬁt from tighter blood
pressure control or use of ACE inhibitors has also been noted
in patients with polycystic kidney disease, a condition that is
not characterized by heavy proteinuria [69, 70].
9.CombinationTherapy
Most patients with CKD require more than one antihyper-
tensive medication for treatment of hypertension. Choosing
agents that have complementary mechanisms of actions or
areindicatedtoaddressothercomorbidconditionsisauseful
strategy to optimize therapy and minimize side eﬀects. Loop
diuretics are often necessary to treat volume overload or
hyperkalemia.
Dual blockade with ACE inhibitors and ARBs reduces
proteinuria to a greater degree than either class alone, but
has not been proven to preserve renal function or improve
cardiovascular outcomes [71]. Of concern is the increased
risk of adverse events observed in the Ongoing Telmisartan
Alone and in Combination with Ramipril Global Endpoint
Trial (ONTARGET) [72]. In this large trial of patients at
high risk for vascular disease, the mean serum creatinine
was approximately 1.1mg/dL, one-third of the participants
were normotensive, and only 13% of patients had microal-
buminuria; dual blockade was associated with worse renal
function and hyperkalemia, and there was no diﬀerence in
cardiovascular events or mortality. Combining aldosterone
antagonists with inhibitors of the RAS, although possessing
additional antiproteinuric eﬀects, should be discouraged
for the same reasons—lack of proven clinical beneﬁt and
increased risk of side eﬀects [73].
The role and safety of combination blockade of the
RAS consisting of a direct renin inhibitor in patients
with CKD are not yet fully elucidated. The Aliskiren in
the Evaluation of Proteinuria in Diabetes (AVOID) trial
studied a group of carefully selected diabetic patients with
GFR >30ml/min/1.73m2 and no evidence of hyperkalemia;
the addition of aliskiren to losartan was well tolerated
and reduced albuminuria [74]. Results of future studies,
including that of an ongoing clinical trial of diabetic patients
with similar degree of CKD as in AVOID [75], may answer
whether combination blockadeof the RASusing direct renin
inhibitors results in improvement of hard clinical endpoints.
10.Nonpharmacologic Therapy
Although pharmacologic therapy is often necessary to con-
trol blood pressure in most patients with CKD, sodium
restriction, smoking cessation, moderate alcohol consump-
tion, weight loss, and regular exercise should be part of a
comprehensive strategy of eﬀective treatment of hyperten-
sion in CKD. Dietary recommendations need to be modiﬁed
according to the stage of CKD to optimally regulate protein,
phosphorus, and potassium intake [47].
11.TreatmentofRenalArteryStenosis
Atherosclerotic renal artery stenosis could cause hyperten-
sion and CKD. Since most lesions are asymptomatic, the
true prevalence is not known. Studies of insurance claims
data and patients undergoing angiography for unrelated
indications report wide variations in prevalence ranging
from 0.5% to as high as 45% [76, 77]. The natural history
of the disease is also controversial, with only a minority of
patients developing progressive renal failure or intractable
hypertension [78]. To date, controlled clinical trials have
not demonstrated the superiority of percutaneous revas-
cularization over medical therapy [79–82]. These studies,
however, spanned a long period of time and employed
diﬀerent interventions, entry criteria, treatment protocols,
and endpoints. Until the results of a large ongoing trial
clarify the role of revascularization [83], medical therapy
of hypertension and other atherosclerotic factors remains
the mainstay of treatment of atherosclerotic renal artery
stenosis. Revascularization may be warranted in patients
with recurrent pulmonary edema, solitary or transplanted
kidney, or worsening renal failure.6 International Journal of Hypertension
12.Treatmentof Hypertensionafter
RenalTransplant
Based on evidence for native chronic kidney disease,
K/DOQI recommends aiming for blood pressure <130/80
in renal transplant recipients. As discussed above, the
applicability of this goal to patients who do not have
proteinuric native kidney disease has not been established.
Whether speciﬁc classes of antihypertensive agents provide
additional beneﬁt to transplant recipients beyond what is
obtained from control of blood pressure per se is also not
known. As long as there are no speciﬁc contraindications
against or compelling indications for a speciﬁc class of
agents, any antihypertensive agent could be used in trans-
plant recipients. Close monitoring is warranted when using
nondihydropyridine calcium channel blockers (diltiazem,
verapamil) and inhibitors of the RAS because the former
inhibit metabolism of immunosuppressive agents by the
cytochrome P450 system, and the latter could result in
hyperkalemia [84, 85].
13.ExperimentalApproaches
Advances in device technology have allowed the resurgence
of invasive prepharmacotherapy interventions for resistant
hypertension that were abandoned because of technical
diﬃculties or excessive morbidity. Preliminary results of
carotid sinus stimulation and catheter-based renal sympa-
thetic denervation suggest that sustained reduction in blood
pressure could be achieved with acceptable risks [86, 87].
If these early results could be replicated in diverse clinical
settings,includingpatientswithCKD,theywouldexpandthe
range of options for the treatment of resistant hypertension.
14.Summary
Treatment of hypertension in CKD patients should take
into consideration the nature of the underlying kidney
disease. Patients with diabetic nephropathy or proteinuric
nondiabetic kidney disease beneﬁt from treatment with
ACE inhibitors or ARBs to a goal blood pressure of
<130/80mmHg, if tolerated. A goal of <140/90mmHg is
acceptable for most patients with other forms of CKD. Dual
or triple blockade of the RAS should generally be avoided.
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